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Introduction
Traditionally, male infertility is diagnosed using World Health 
Organization (WHO) standard parameters which are published in a 
laboratory manual providing guidelines to laboratories for processing 
human semen and cut-off values to determine normality or abnormality 
[1]. Since publication of the first manual in 1980 there have been a 
number of updates released with the latest two editions being the 4th 
Edition in 1999 and the 5th Edition in 2010 [2]. Substantial changes 
between the two editions have resulted in the same patient being 
diagnosed (under the 5th Edition guidelines) with a normal semen 
analysis when they would have been diagnosed with an abnormal 
semen analysis had the laboratory used the previous version cut-off 
values. However, the application and reference values presented in the 
4th Edition resulted from vague reference populations and therefore 
lacked transparency, resulting in little consensus around the accuracy 
of these values [3,4]. Furthermore this was acknowledged by the WHO 
[2,5]. Although the 5th Edition has included clearly defined reference 
ranges, concerns have been raised over the studies that generated these 
values [2] and so debate has ensued over its legitimacy leaving no 
definitive agreement between laboratories as to which edition should 
be used [6].
While semen analysis is regarded as a key tool to evaluate male 
infertility [4] in spite of which reference values are used [7] it does 
not consider sperm DNA integrity. DNA fragmentation testing whilst 
considered useful, has not yet been universally accepted due to a lack of 
standardization of tests and protocols [8]. 
Since about 15% of infertile men undergoing a semen analysis will 
have semen within normal parameters [9,10], there has been a focus 
on sperm DNA fragmentation and its association with infertility. 
Elevated levels of DNA fragmentation have been linked with infertile 
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Abstract
Background: As a standard reference to evaluate male factor infertility, the majority of fertility laboratories use 
the 4th or 5th Editions of the World Health Organization’s semen analysis guidelines. Following the release of the 5th 
Edition, debate over its legitimacy has resulted in some laboratories using the 4th and others the 5th Edition. DNA 
integrity tests have been shown to be a valuable adjunct to semen analysis and have subsequently been adopted 
by many fertility laboratories. This study explored the prevalence of samples with high DNA fragmentation levels 
according to semen analysis categories using both the 4th and the 5th Edition reference ranges.
Materials and Methods: The study included 905 consecutive semen samples from 863 infertile couples 
attending a fertility clinic. A semen analysis was conducted according to both the 4th and 5th Edition guidelines 
published by the World Health Organization. DNA damage was assessed using the Halosperm G2 test kit and 
expressed as a percentage DNA fragmentation level.
Results: Alongside both the World Health Organization 4th and 5th Edition semen analysis criteria abnormal 
DNA fragmentation levels were more common in abnormal semen samples however elevated DNA fragmentation 
levels were also found in normal semen samples using the same criteria. Of the samples that were graded as 
normozoospermic according to the 5th Edition guidelines 16% were deemed to have elevated DNA fragmentation 
levels compared to 11.7% graded by the 4th Edition guidelines. The number of normozoospermic samples, graded 
according to the 5th Edition guidelines was significantly higher (n=697) than when the same samples were graded 
according to 4th Edition guidelines (n=385) (p=0.001). A significant proportion of samples with an abnormal DNA 
fragmentation level corresponding to the World Health Organisation 4th and 5th Edition criteria were evident in 
normozoospermic (p <0.05), normoteratozoospermic (p=<0.005) and normoasthenozoospermic (p<0.05) samples.
Conclusion: Our findings indicate that abnormal DNA fragmentation levels are proportionate to the World Health 
Organisation semen analysis criteria with fragmentation levels increasing according to the increasing number of 
semen analysis abnormalities. In some cases however, abnormal fragmentation levels were recorded when semen 
analysis was normal and normal fragmentation levels were recorded where the semen analysis was considered 
abnormal.
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men [10-14], poor fertilization rates [15,16], specific semen defects 
[17], miscarriage and poor artificial reproductive technology results 
[18]. Furthermore, infertile men have been shown to have substantially 
higher levels of DNA fragmentation than fertile men [13] and hence 
DNA fragmentation testing has been proposed as a valuable adjunct 
to routine semen analysis when considering the fertility potential of a 
man [16].
Although DNA fragmentation testing can be conducted in a 
number of ways, the Halosperm assay has been described as a ‘cheap 
and convenient’ test [18] that has a relatively short and simple protocol 
with correlations having been observed with some of the most 
commonly recognised tests [11,19-21]. The aim of this study was to 
formally investigate the clinical significance of the Halosperm test and 
assess its relationship to the two most recent WHO semen analysis 
guidelines.
Materials and Methods
We studied 905 consecutive semen samples from 863 men who 
underwent semen analysis and DNA fragmentation testing using 
the Halosperm assay as part of their fertility treatment. The study 
was approved by the Edith Cowan University Human Research 
Ethics committee and the Joondalup Health Campus Human Ethics 
Committee.
Semen analysis
Men were instructed to have 2 to 5 days sexual abstinence before 
producing a semen sample for analysis. Semen samples were collected 
by masturbation into a clean 60 ml wide-mouthed universal container 
and processed within 1 hour of ejaculation and liquefaction. Semen 
analysis was performed according to the WHO 4th Edition guidelines 
[22] for volume, concentration, motility and morphology. Semen 
samples were then classified according to both WHO 4th and 5th 
Edition criteria [1] as shown in Table 1. 
Following semen analysis, DNA fragmentation analysis was carried 
out using the Halosperm G2 test kit (Halotech DNA SL). Details of 
this procedure have been described elsewhere [23] but briefly, semen 
samples were mixed with a liquefied agarose gel and placed onto 
a pre-coated slide. The slides were refrigerated for 5 minutes before 
being treated with a denaturing agent, followed by a lysis solution and 
finally staining solutions. The criteria to determine fragmented and 
non-fragmented DNA was followed according to the manufacturer’s 
instructions. In essence spermatozoa with a large or medium sized 
halo depict unfragmented DNA whilst those with either a small halo 
or without a halo and those with a weak or irregular stained core depict 
fragmented DNA. The DNA Fragmentation Levels (DFL) for each 
sample was assessed by counting a minimum of 300 sperm under the 
x100 objective of the microscope. The numbers of sperm judged to have 
fragmented DNA were expressed as a percentage of the total number. 
Samples with a reading of >30% were deemed abnormal.
Statistical Analysis 
Pearson correlations and analysis by ANOVA were performed to 
study the relationship between sperm DNA fragmentation and semen 
analysis results with post-hoc testing by Tukey’s HSD and proportions 
compared by a Chi-squared test. The minimum level of significance 
was set at P <0.05. Microsoft Excel and StatistiXL (Nedlands, Western 
Australia) statistical packages were used to perform all statistical 
analyses. 
Results
Semen quality according to different WHO criteria
Using the reference ranges in the WHO manual 4th Edition, 
385/905 (42.5%) semen samples were classed as normozoospermic 
with the remainder having 1 or more abnormalities as shown in Table 
2. However, classification of the same samples using the reference 
ranges provided in the WHO manual 5th Edition showed that 697/905 
(77.0%) were said to be normozoospermic, simply as a consequence of 
lower limits of normality. Table 2 also shows that of the 520 samples 
with 1 or more abnormalities according to WHO 4th Edition, 78 (25%) 
had the same number when classisfied according to WHO 5th Edition 
and 442 (85%) had a reduction in the number of abnormalities.
Semen analysis and DNA fragmentation
A summary of the 905 semen analysis results and their correlation 
with the corresponding DNA fragmentation results is shown in Table 
3. A significant positive correlation was seen between SDF and sexual 
abstinence (ie longer abstinence associated with higher SDF), whereas 
significant negative correlations (ie lower semen quality associated 
with higher SDF) were seen between SDF and sperm concentration, 
motility and morphology.
The mean DNA fragmentation results according to semen quality 
are shown in Table 4. The only statistically significant difference in DFLs 
between samples classified under the 4th and 5th Editions was for the 
normozoospermic samples. However, for both classification systems as 
shown in Table 4, there were significant increases in the DFLs as the 
severity of semen abnormalities increased.
Abnormalities
WHO 5th Edition
0 1 2 3 Total
WHO 4th Edition
0 385 0 0 0 385
1 233 46 0 0 279
2 72 81 19 0 172
3 7 25 24 13 69
Total 697 152 43 13 905
Table 2: The number of abnormalities (sperm concentration, motility or morphology) 
in 905 semen samples when classified according to the reference ranges of WHO 
4th and 5th Edition manuals.
Semen Parameters WHO 4th Edition WHO 5th Edition
Volume (mL) 2 1.5
Sperm Concentration (106/mL) 20 15
Motility 50% (a + b)* 32% (a + b)*
Morphology (% normal) 14 4
*Grade a=rapid progressive motility (>25 µm/s), *Grade b=slow/sluggish 
progressive motility (5-25 µm/s).
Table 1: WHO 4th Edition and WHO 5th Edition semen analysis criteria cut off 
values. (Adapted from Esteves, et al. [28]).
Values are presented as mean ± SEM.
*Significant association.
Table 3: Pearson Correlation for DNA fragmentation level to corresponding semen 
parameters, 905 samples from 863 men were analysed.
Variable Value Pearson’s r P value
Abstinence (days ± SEM) 4.1 ± 0.2  0.11 0.001*
Volume (ml ± SEM) 3.5 ± 0.1  0.05 0.159
Sperm concentration (x106/ml ± SEM) 68.6 ± 2.2 -0.17 0.000*
Sperm motility (% ± SEM) 59.0 ± 0.6 -0.30 0.000*
Sperm morphology (% ± SEM) 14.0 ± 0.2 -0.24 0.000*
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Samples classified as OAT by the 4th Edition semen analysis criteria 
had significantly higher DFLs than O (p<0.01) as did the samples 
classified by the 5th Edition (p<0.001). NA samples, classified under 
both 4th and 5th Edition criteria had significantly higher DFLs than N 
samples (p<0.001 and p<0.0001 respectively). 
Comparing means of DFL for the various categories of semen 
quality is limited in that each group will have a mixture of samples 
with normal and clinically abnormal levels of DFL. Table 5 shows 
another way of looking at this by considering the proportion of semen 
samples that registered an abnormal sperm DFL (>30%) according to 
the corresponding semen analysis classification. 
Samples recorded with sperm concentration, morphology and 
progressive motility levels outside of the WHO 4th and 5th Edition 
reference, revealed the highest proportion of samples with abnormal 
DFL (>30%), whilst the lowest proportion of samples with abnormal 
DFLs were shown to be within normal limits for all concentrations, 
morphology and progressive motility regardless of which manual’s 
criteria were used.
Discussion
Semen analysis is intended as a screening test to identify potential 
sub-fertility in men. As such, the test must be conducted under standard 
conditions so that the results of one man may be compared directly 
with others. This includes a standard period of sexual abstinence prior 
to production of the sample, as well as the use of standardized analytical 
procedures. To this end, the WHO have produced a series of manuals 
which include guidelines on the performance of semen analysis, and 
a series of reference ranges against which the samples may be judged. 
These manuals have undergone periodic revision and the last two 
editions, the 4th and 5th, are the ones in most frequent use these days.
This study has evaluated the relationships between semen quality as 
determined using both the WHO 4th and 5th Edition semen analysis 
criteria, and DFLs as identified by the Halosperm G2 test kit. The results 
reveal significantly higher DFLs in samples that have been classified 
as being abnormal compared with those with a semen analysis within 
normal parameters regardless of which edition of the WHO guidelines 
are used. Oligoasthenoteratozoospermic samples had the highest 
DFLs when compared to oligozoospermic, teratozoospermic and 
asthenozoospermic samples and it was evident that the proportion of 
samples with abnormal DFLs was higher when the WHO 5th Edition 
semen analysis criteria were applied compared to the 4th Edition 
criteria. No statistical difference was observed however between the 
specifically categorised semen defects when the two different guidelines 
were applied. Only samples with both abnormal motility and 
morphology, as scored using the 4th Edition criteria, showed a mean 
abnormal DFL. In contrast, all samples with some abnormality scored 
using 5th Edition semen analysis criteria revealed a mean abnormal 
DFL. The general finding that there is an inverse relationship between 
DFL and sperm morphology and motility, i.e. higher DFL when the 
proportion of sperm with normal morphology and motility is reduced, 
concurs with other reports [17,24-27].
Semen samples showed an inverse relationship between sperm 
concentration with DFL. This is in accord with Irvine et al., [25] who 
used WHO 3rd Edition criteria which has the same sperm concentration 
criteria as the 4th Edition [28]. Nevertheless, the proportion of samples 
with normal parameters according to the WHO 4th and 5th Editions 
but with DFLs >30% were 11.7% and 16% respectively. This is aligned 
with others’ findings whereby approximately 15% of infertile men 
tested have semen within normal parameters [9,10]. Table 5 shows 
that a higher proportion of semen samples with normal sperm 
concentrations according to the 5th Edition but abnormalities of sperm 
Semen quality
Abnormal SDF/Total (%)
WHO 4th Edition WHO 5th Edition P value
Oligozoospermia (O) 6/31 (19.4%) 31/99 (31.3%) 0.100
Oligoteratozoospermia (OT) 22/77 (28.6%) 7/18 (38.9%) 0.195
Oligoasthenozoospermia (OA) 4/10 (40.0%) 10/21 (47.6%) 0.345
Oligoasthenoteratozoospermia (OAT) 37/69 (53.6%) 10/13 (76.9%) 0.060
Normozoospermic (N) 45/385 (11.7%) 112/697 (16.0%) 0.025*
Normoteratozoospermia (NT) 34/203 (16.8%) 9/21 (42.9%) 0.002*
Normoasthenozoospermia (NA) 13/45 (28.9%) 17/32 (53.1%) 0.016*
Normoasthenoteratozoospermia (NAT) 38/85 (44.7%) 3/4 (75.0%) 0.117
*Significant association.
Table 5: Proportion of samples with abnormal DNA fragmentation levels (>30%) corresponding to WHO 4th Edition and WHO 5th Edition semen analysis criteria.
Semen Quality
WHO 4th Edition WHO 5th Edition Significance between 4
th 
and 5th Editions
n SDF (%) n SDF (%) p
Oligozoospermia (O) 31 23.3 ± 2.8th 99 27.0 ± 1.7l,o,p NS
Oligoteratozoospermia (OT) 77 27.6 ± 2.0e,i 18 31.0 ± 4.4 NS
Oligoasthenozoospermia (OA) 10 28.1 ± 6.4 21 33.4 ± 4.3m NS
Oligoasthenoteratozoospermia (OAT) 69 37.0 ± 2.6d,g,h,i 13 46.6 ± 5.8n,p NS
Normozoospermic (N) 385 17.5 ± 0.6a,b,c,d,e,j 697 20.3 ± 0.6j,k,l,m,n 0.001
Normoteratozoospermia (NT) 203 21.8 ± 1.2c,f,g 21 29.9 ± 4.9 NS
Normoasthenozoospermia (NA) 45 28.0 ± 3.2a 32 39.4 ± 4.6k,o NS
Normoasthenoteratozoospermia (NAT) 85 30.7 ± 2.1b,f 4 36.1 ± 9.6 NS
Statistical differences within the same manual edition are represented with the same superscript and are significantly different (p<0.05). NS=Not significant.
Table 4: DNA Fragmentation levels (mean ± SEM) corresponding to semen parameters classified according to different WHO semen analysis editions (n=905).
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morphology and/or motility have significantly elevated DFLs. The 
inclusion of a test of sperm DNA fragmentation is therefore important 
in providing additional information about the condition of the sperm. 
Men producing samples with abnormal DFLs may therefore approach 
assisted reproduction with a number of different strategies to help 
achieve a pregnancy, including the use of antioxidants [29], ICSI [16] 
or frequent ejaculation [30].
In summary, the present study has shown that there is an 
association between semen quality and DFL. The measurement of 
sperm DNA fragmentation does give further information on which to 
base decisions regarding future treatment. Care should also be taken 
as the reference range used in interpreting the semen analysis does 
influence the prevalence of abnormal DFL.
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